- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Most-Popular Center for Biosimilars® Interviews of 2020
Here are some of our most-popular biosimilar interviews for all of 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are some of our most-popular biosimilar interviews for all of 2020.
Soumi Saha, PharmD, JD, senior director of advocacy at Premier, discusses drug shortages caused by coronavirus disease 2019 (COVID-19) and policy recommendations that could fix the problem.
Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, explains potential consequences if the United States were to do away with biosimilars.
Will Gatziolis, MBA, an associate principal at ZS, explains how the COVID-19 pandemic will help biosimilar uptake and what manufacturers can do to take advantage of this opportunity.
Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market, at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
An additional interview features Byoungseo Choi, head of marketing for Celltrion Healthcare, who discussed how Celltrion's infliximab biosimilar can aid in the treatment of COVID-19–related inflammation, as well as the company’s launch plans for biosimilars through 2030.
To read all these articles and more, visit centerforbiosimilars.com.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
